

TRACER (S1415CD) NEWSLETTER



February 2019

STUDY UPDATES

- ✦ As of 2/19/2019, 2,663 patients are registered to the study.
- ✦ **SWOG Group Meeting:** We will hold a site meeting at the Spring SWOG Group Meeting on Thursday morning (4/25) from 8AM-10AM. We hope to see you all there!
- ✦ We are not on track to meeting the accrual goal by the funder's deadline of 03/31/19. We are working on a plan with our funders and ask that you **continue accruing patients past the deadline.** You will continue to receive the \$750 per patient enrolled.

TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR and funded in part by PCORI.

THANK YOU TO OUR TOP ACCRUERS

CONGRATULATIONS TO MARSHFIELD WINCORN IN MARSHFIELD, WI AND GEISINGER MEDICAL CENTER IN DANVILLE, PA FOR REACHING 100% ACCRUAL

CONGRATULATIONS TO OUR TOP ACCRUERS FOR THE MONTH OF JANUARY:


- ★ Marshfield WinCorp in Marshfield, WI (11 accruals)
- ★ St. Joseph Mercy Hospital in Ann Arbor, MI (9 accruals)
- ★ University of New Mexico Cancer Center in Albuquerque, NM (9 accruals)
- ★ Dixie Regional Medical Center Cancer Center in Saint George, UT (9 accruals)
- ★ Doctors' Cancer Center in Manati, PR (8 accruals)
- ★ Baptist Memorial Hospital & Cancer Center in Memphis, TN (8 accruals)

PERCENTAGE OF RECRUITMENT COMPLETED


Percent of recruitment target complete	Number of Clinical Sites						
	Arm 1: Cohort	Arm 2: Usual Care		Arm 3: Intervention		Arm 4: Intervention	
		Low/High Risk Accrual	Intermediate Risk Accrual	Low/High Risk Accrual	Intermediate Risk Accrual	Low/High Risk Accrual	Intermediate Risk Accrual
100%	6	3	0	6	5	4	0
75-99%	3	3	2	1	0	2	1
50-74%	3	0	0	2	3	3	2
25-49%	1	1	4	0	0	2	4
< 25%	0	1	2	3	4	1	5
Total	13	8	8	12	12	12	12

Updated 02-19-2019

TrACER Total Accrual as of February 19, 2019



TrACER Accrual in the Past 12 Months



Contact Us

Site Requirements, including regimen questions: HICOR ▪ TrACER@fredhutch.org ▪ 206-667-7624
 Patient eligibility, study procedures, and data submission:
 SWOG SDMC ▪ cancercontrolquestion@crab.org ▪ 206-652-2267